Novel drug combinations pave the way for personalized leukemia therapies

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have published a review on BH3 mimetics—a new class of drugs that are reshaping the treatment landscape for acute myeloid leukemia (AML), one of the most aggressive and treatment-resistant blood cancers. The work is published in Nature Reviews Clinical Oncology.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup